The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Metronomics: towards personalized chemotherapy?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 846
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Rougier, P., Adenis, A., Ducreux, M., de Forni, M., Bonneterre, J., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00072-1 · Cited by 751
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Self-citationButler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 570
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
(2002) · PubMed · Cited by 457
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
A change of strategy in the war on cancer
Gatenby, R. A. (2009) · Nature · doi:10.1038/459508a · Cited by 402
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, D. J., & Kerbel, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4238 · Cited by 385
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A.-F., Vaka, D., Tran, K. Q. T., Zhou, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358
Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.017 · Cited by 346
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C.-H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., Hicks, J. K., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.4 · Cited by 329
Immunogenic cancer cell death: a key-lock paradigm
Tesniere, A., Apetoh, L., Ghiringhelli, F., Joza, N., Panaretakis, T., Kepp, O., Schlemmer, F., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.007 · Cited by 307
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., & Kerbel, R. S. (2005) · Blood · doi:10.1182/blood-2005-04-1422 · Cited by 253
Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 252
Pasquier, E., Ciccolini, J., Carre, M., Giacometti, S., Fanciullino, R., Pouchy, C., Montero, M.-P., Serdjebi, C., Kavallaris, M., & André, N. (2011) · Oncotarget · doi:10.18632/oncotarget.343 · Cited by 234
Self-citationZhao, J., Cao, Y., Lei, Z., Yang, Z., Zhang, B., & Huang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0283 · Cited by 211
Kieran, M. W., Turner, C. D., Rubin, J. B., Chi, S. N., Zimmerman, M. A., Chordas, C., Klement, G., Laforme, A., Gordon, A., Thomas, A., et al. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000183863.10792.d4 · Cited by 199
Kummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
Bottini, A., Generali, D., Brizzi, M. P., Fox, S. B., Bersiga, A., Bonardi, S., Allevi, G., Aguggini, S., Bodini, G., Milani, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5773 · Cited by 189
Kerbel, R. S., Klement, G., Pritchard, K. I., & Kamen, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf093 · Cited by 177
Has the time come for metronomics in low-income and middle-income countries?
André, N., Banavali, S., Snihur, Y., & Pasquier, E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70056-1 · Cited by 174
Self-citationWerno, C., Menrad, H., Weigert, A., Dehne, N., Goerdt, S., Schledzewski, K., Kzhyshkowska, J., & Brune, B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq088 · Cited by 167
Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 165
Pasquier, E., Street, J., Pouchy, C., Carre, M., Gifford, A. J., Murray, J., Norris, M. D., Trahair, T., Andre, N., & Kavallaris, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.205 · Cited by 162
Self-citationMetronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
Glode, L. M., Barqawi, A., Crighton, F., Crawford, E. D., & Kerbel, R. (2003) · Cancer · doi:10.1002/cncr.11713 · Cited by 162
Neurocognitive function after radiotherapy for paediatric brain tumours
Padovani, L., André, N., Constine, L. S., & Muracciole, X. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.182 · Cited by 160
Self-citationCerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V., Rouvinen, N., Tuuminen, T., Laasonen, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.113 · Cited by 159
Kandalaft, L. E., Powell, Jr., Chiang, C. L., Tanyi, J., Kim, S., Bosch, M., Montone, K., Mick, R., Levine, B. L., Torigian, D. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.22664 · Cited by 159
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 156
Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M., Ackland, S. P., Fitzharris, B. M., van Hazel, G., Wilcken, N. R. C., Grimison, P., Nowak, A. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9101 · Cited by 150
Pasquier, E., André, N., & Braguer, D. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907781662266 · Cited by 149
Self-citationBerruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 146
Response of recurrent medulloblastoma to low-dose oral etoposide.
Ashley, D. M., Meier, L., Kerby, T., Zalduondo, F. M., Friedman, H. S., Gajjar, A. J., Kun, L. E., Duffner, P. K., Smith, S. C., & Longee, D. C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1922 · Cited by 131
Hsu, C., Shen, Y., Lin, Z.-Z., Chen, P.-J., Shao, Y.-Y., Ding, Y.-H., Hsu, C., & Cheng, A.-L. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.035 · Cited by 130
Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L., & Cerundolo, V. (2003) · PubMed · Cited by 128
Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J. A., Yeh, B. M., Lake, D. E., Dang, C. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0141 · Cited by 127
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
Peyrl, A., Chocholous, M., Kieran, M. W., Azizi, A. A., Prucker, C., Czech, T., Dieckmann, K. U., Schmook, M. T., Haberler, C., Leiss, U., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24006 · Cited by 124
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Kesari, S., Schiff, D., Doherty, L. M., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O’Neill, A., Drappatz, J., Chen‐Plotkin, A. S., Ramakrishna, N. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-006 · Cited by 121
Ellebæk, E., Engell-Noerregaard, L., Iversen, T. Z., Frøsig, T. M., Ahmad, S. M., Hadrup, S. R., Andersen, M. H., & Svane, I. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1242-4 · Cited by 121
Pharmacogenetics and Pharmacogenomics: a Bridge to Individualized Cancer Therapy
Weng, L., Zhang, L., Peng, Y., & Huang, R. S. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.213 · Cited by 119
Chemotherapeutic drugs—more really is not better
Fidler, I. J., & Ellis, L. M. (2000) · Nature Medicine · doi:10.1038/74969 · Cited by 117
Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0682 · Cited by 115
Hashimoto, K., Man, S., Xu, P., Cruz‐Muñoz, W., Tang, T., Kumar, R., & Kerbel, R. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0960 · Cited by 113
Hackl, C., Man, S., Francia, G., Milsom, C., Xu, P., & Kerbel, R. S. (2012) · Gut · doi:10.1136/gutjnl-2011-301585 · Cited by 109
Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now
Prendergast, G. C., & Jaffee, E. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4626 · Cited by 108
High-Time Chemotherapy or High Time for Low Dose
Kamen, B. A., Rubin, E., Aisner, J., & GLATSTEIN, E. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2935 · Cited by 104
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 103
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro, A. M. P., Chan, T. A.-T., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., DeAngelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos295 · Cited by 102
Kaneno, R., Shurin, G. V., Kaneno, F. M., Naiditch, H., Luo, J., & Shurin, M. R. (2011) · Cellular Oncology · doi:10.1007/s13402-010-0005-5 · Cited by 100
Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Rich, J. N., McLendon, R. E., Herndon, J. E., Marcello, J. E., Threatt, S., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0403-6 · Cited by 98
Watanabe, T., Sano, M., Takashima, S., Kitaya, T., Tokuda, Y., Yoshimoto, M., Kohno, N., Nakagami, K., Iwata, H., Shimozuma, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3939 · Cited by 97
Chen, C., Ho, C., Chang, M., Sun, W.-Z., Chen, Y., Chiang, Y., Syu, M.-H., Hsieh, C., & Cheng, W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.34 · Cited by 96
Vives, M., Morell, M., Gracova, K., Graupera, M., Casanovas, O., Capellá, G., Serrano, T., Laquente, B., & Viñals, F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28259 · Cited by 95
Addeo, R., Sgambato, A., Cennamo, G., Montella, L., Faiola, V., Abbruzzese, A., Capasso, E., Leo, L., Botti, G., Caraglia, M., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.039 · Cited by 94
Baruchel, S., Diezi, M., Hargrave, D. R., Stempak, D., Gammon, J., Moghrabi, A., Coppes, M. J., Fernandez, C. V., & Bouffet, É. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.023 · Cited by 89
Stempak, D., Gammon, J., Halton, J., et al. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000243657.64056.c3 · Cited by 88
Cham, K. K., Baker, J. H. E., Takhar, K. S., Flexman, J. A., Wong, M. Q., Owen, D. A., Yung, A. C., Kozłowski, P., Reinsberg, S. A., Chu, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605727 · Cited by 87
Zapletalová, D., André, N., Deak, L., Kýr, M., Bajčiová, V., Múdrý, P., Dubská, L. Z., Demlová, R., Pavelka, Z., Zitterbart, K., et al. (2012) · Oncology · doi:10.1159/000336483 · Cited by 86
Self-citationMir, O., Dômont, J., Cioffi, A., Bonvalot, S., Boulet, B., Pechoux, C. L., Terrier, P., Spielmann, M., & Cesne, A. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.025 · Cited by 86
Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B. H., Zhang, L., Xu, P., Man, S., Oliveira, I. D., Yeger, H., Kerbel, R. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0078 · Cited by 83
Briasoulis, E. C., Aravantinos, G., Kouvatseas, G., Pappas, P., Biziota, E., Sainis, I., Makatsoris, T., Varthalitis, I. I., Xanthakis, I., Vassias, A., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-263 · Cited by 80
Integrating pharmacogenetics into gemcitabine dosing—time for a change?
Ciccolini, J., Mercier, C., Dahan, L., & André, N. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.1 · Cited by 79
Self-citationSierro, S. R., Donda, A., Perret, R., Guillaume, P., Yagita∥, H., Lévy, F., & Romero, P. J. (2011) · European Journal of Immunology · doi:10.1002/eji.201041235 · Cited by 78
Vinorelbine in previously treated advanced childhood sarcomas
Casanova, M., Ferrari, A., Spreafico, F., Terenziani, M., Massimino, M., Luksch, R., Cefalo, G., Polastri, D., Marcon, I. G., & Bellani, F. F. (2002) · Cancer · doi:10.1002/cncr.10600 · Cited by 75
Minard‐Colin, V., Ichante, J.-L., Nguyen, L., Paci, A., Orbach, D. H., Bergeron, C., Defachelles, A. S., André, N., Corradini, N., Schmitt, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.012 · Cited by 73
Self-citationBhatt, R. S., Merchan, J. R., Parker, R. A., Wu, H., Zhang, L., Seery, V. J., Heymach, J. V., Atkins, M. B., McDermott, D. F., & Sukhatme, V. P. (2010) · Cancer · doi:10.1002/cncr.24902 · Cited by 72
Pilot study of a pediatric metronomic 4-drug regimen
André, N., Abed, S., Orbach, D. H., Armari‐Alla, C., Padovani, L., Pasquier, E., Gentet, J. C., & Verschuur, A. C. (2011) · Oncotarget · doi:10.18632/oncotarget.358 · Cited by 72
Self-citationMetronomic chemotherapy: an antiangiogenic scheduling
Laquente, B., Viñals, F., & Germà, J. R. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0018-3 · Cited by 71
Chen, C.-S., Doloff, J. C., & Waxman, D. J. (2014) · Neoplasia · doi:10.1593/neo.131910 · Cited by 70
Mannel, R. S., Brady, M. F., Kohn, E. C., Hanjani, P., Hiura, M., Lee, R., DeGeest, K., Cohn, D. E., Monk, B. J., & Michael, H. T. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.013 · Cited by 70
Allegrini, G., Desidero, T. D., Barletta, M. T., Fioravanti, A., Orlandi, P., Canu, B., Chericoni, S., Loupakis, F., Paolo, A. D., Masi, G., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9260-6 · Cited by 70
Emmenegger, U., Morton, G., Francia, G., Shaked, Y., Franco, M., Weinerman, A. S., Man, S., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2598 · Cited by 69
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich, F., Landi, L. M., Lombardi, G., Porta, C., Galli, L., Fontana, A., AMOROSO, D., Galli, C., Andreuccetti, M., Falcone, A., et al. (2013) · PubMed · Cited by 69
Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., & Kerbel, R. S. (2011) · Neoplasia · doi:10.1593/neo.101174 · Cited by 68
Felgenhauer, J. L., Nieder, M. L., Krailo, M., Bernstein, M. L., Henry, D. W., Malkin, D. M., Baruchel, S., Chuba, P. J., Sailer, S. L., Brown, K., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24328 · Cited by 64
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.
Kan, S., Hazama, S., Maeda, K., Inoue, Y., Homma, S., Koido, S., Okamoto, M., & Oka, M. (2012) · PubMed · Cited by 62
The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
Thakur, M. D., & Stuart, D. D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1633 · Cited by 61
Pasquier, E., Tuset, M., Street, J. A., Sinnappan, S. M., MacKenzie, K. L., Braguer, D., André, N., & Kavallaris, M. (2012) · Angiogenesis · doi:10.1007/s10456-012-9321-x · Cited by 60
Self-citationPanetta, J. C., Schaiquevich, P. S., Santana, V. M., & Stewart, C. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1243 · Cited by 59
Oral Etoposide for Refractory and Relapsed Neuroblastoma
Kushner, B. H., Kramer, K., & Cheung, N. V. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3221 · Cited by 57
YAN, H. H., Chen, X., Zhang, Q., Qin, J., Li, H., Liu, C., Calhoun‐Davis, T., Coletta, L. D., Klostergaard, J., Fokt, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024397 · Cited by 57
Pai, P., Vaidya, A. W., Prabhash, K., et al. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117024 · Cited by 56
Crivellari, D., Gray, K. P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K. N., Láng, I., Gianni, L., Spazzapan, S., Pinotti, G., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.01.015 · Cited by 56
Sánchez‐Muñoz, A., Mendiola, C., Pérez-Ruiz, E., Rodríguez‐Sánchez, C. A., Jurado, J. M., Alonso-Carrión, L., Ghanem, I., de Velasco, G., Blanco, C. Q., & Alba, E. (2010) · Oncology · doi:10.1159/000320602 · Cited by 55
Geary, S. M., Lemke-Miltner, C. D., Lubaroff, D. M., & Salem, A. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067904 · Cited by 54
Cao, H. S. T., Bouvet, M., Kaushal, S., Keleman, A. M., Romney, E., Kim, G., Fruehauf, J. P., Imagawa, D. K., Hoffman, R. M., & Katz, M. H. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0201 · Cited by 52
Perroud, H. A., Rico, M. J., Alasino, C. M., Queralt, F., Mainetti, L. E., Pezzotto, S. M., Rozados, V. R., & Scharovsky, O. G. (2013) · Future Oncology · doi:10.2217/fon.12.196 · Cited by 51
Russell, H. V., Groshen, S. G., Ara, T., DeClerck, Y. A., Hawkins, R. A., Jackson, H. A., Daldrup-Link, H. E., Marachelian, A., Skerjanec, A., Park, J. R., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22821 · Cited by 49
Drug repurposing in pediatrics and pediatric hematology oncology
Blatt, J., & Corey, S. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.009 · Cited by 48
Phase II study of 21 day schedule oral etoposide in children
Davidson, A., Gowing, R., Lowis, S. P., Newell, D. R., Lewis, I. J., Dicks-Mireaux, C., & Pinkerton, R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00201-3 · Cited by 47
Kontopodis, E., Hatzidaki, D., Varthalitis, I. I., Kentepozidis, N. K., Giassas, S., Pantazopoulos, N., Vardakis, N., Rovithi, M. N., Georgoulias, V., & Agelaki, S. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000050 · Cited by 47
Kelley, R. K., Hwang, J. H., Magbanua, M. J. M., Watt, L., Beumer, J. H., Christner, S. M., Baruchel, S., Wu, B., Fong, L. H., Yeh, B. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.553 · Cited by 46
Mayer, E. L., Isakoff, S. J., Klement, G. L., Downing, S. R., Chen, W. Y., Hannagan, K., Gelman, R. S., Winer, E. P., & Burstein, H. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2256-5 · Cited by 45
Todaro, M., Meraviglia, S., Caccamo, N., Stassi, G., & Dieli, F. (2013) · OncoImmunology · doi:10.4161/onci.25821 · Cited by 45
Kim, Y., Lee, H., Kim, T., Eisinger‐Mathason, T. S. K., Zhang, A. Y., Schmidt, B. H., Karl, D. L., Nakazawa, M. S., Park, P. J., Simon, M. C., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27666 · Cited by 45
Francia, G., Man, S., Lee, C.-J., Lee, C. R., Xu, P., Mossoba, M. E., Emmenegger, U., Medin, J. A., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0931 · Cited by 44
Metronomic Scheduling of Anticancer Treatment: The Next Generation of Multitarget Therapy?
André, N., Padovani, L., & Pasquier, E. (2011) · Future Oncology · doi:10.2217/fon.11.11 · Cited by 44
Self-citationKerbel, R. S., Guérin, É., Francia, G., Xu, P., Lee, C. R., Ebos, J. M. L., & Man, S. (2013) · The Breast · doi:10.1016/j.breast.2013.07.011 · Cited by 43
Francia, G., Shaked, Y., Hashimoto, K., Sun, J., Yin, M., Cesta, C. E., Xu, P., Man, S., Hackl, C., Stewart, J. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0659 · Cited by 43
Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study Group
Dantonello, T. M., Winkler, P., Boelling, T., Friedel, G., Schmid, I., Mattke, A. C., Ljungman, G., Bielack, S., Klingebiel, T. E., Kościelniak, E., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22862 · Cited by 42
Ladoire, S., Eymard, J., Zanetta, S., Mignot, G., Martin, E., Kermarrec, I., Mourey, E., Michel, F., Cormier, L., & Ghiringhelli, F. (2010) · PubMed · Cited by 41
Dellapasqua, S., Mazza, M., Rosa, D., Ghisini, R., Scarano, E., Torrisi, R., Maisonneuve, P., Viale, G., Cassano, E., Veronesi, P., et al. (2011) · The Breast · doi:10.1016/j.breast.2011.02.014 · Cited by 40
Correale, P., Botta, C., Basile, A., Pagliuchi, M., Licchetta, A., Martellucci, I., Bestoso, E., Apollinari, S., Addeo, R., Misso, G., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.2.15722 · Cited by 40
Addeo, R., Sperlongano, P., Montella, L., Vincenzi, B., Carraturo, M., Iodice, P., Russo, P., Parlato, C., Salzano, A., Cennamo, G., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1945-4 · Cited by 39
Interaction between regulatory T cells and cancer stem cells
Yu, X., Li, H. Z., & Ren, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.27634 · Cited by 39
Gebbia, V., Serretta, V., Borsellino, N., & Valerio, M. R. (2011) · Urology · doi:10.1016/j.urology.2011.08.010 · Cited by 38
Soriano, J. L., Batista, N., Santiesteban, E. R., Lima, M., González, J. G., García, R., Zarza, Y., López, M. V., Rodríguez, M., Fernández, J. L. L., et al. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/710292 · Cited by 38
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy
Landreneau, J. P., Shurin, M. R., Agassandian, M., Keskinov, A. A., Ma, Y., & Shurin, G. V. (2013) · Cancer Microenvironment · doi:10.1007/s12307-013-0141-3 · Cited by 37
Investigating a pathogenic role for TXNDC5 in tumors
Chang, X., Xu, B., Wang, L., Wang, Y., Wang, Y., & Yan, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2123 · Cited by 37
Efficacy and Tolerability of Vinorelbine in the Cancer Therapy
Galano, G., Caputo, M., Tecce, M. F., et al. (2011) · Current Drug Safety · doi:10.2174/157488611797579302 · Cited by 37
He, S., Shen, J., Hong, L., Niu, L., & Niu, D. (2011) · Medical Oncology · doi:10.1007/s12032-010-9791-x · Cited by 36
Herrlinger, U., Rieger, J., Steinbach, J. P., N�gele, T., DICHGANS, J., & Weller, M. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-1726-y · Cited by 35
In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
Thoenes, L., Hoehn, M., Kashirin, R., Ogris, M., Arnold, G. J., Wagner, E., & Guenther, M. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.02.019 · Cited by 35
Li, S. C., Lee, K. L., & Luo, J. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0267 · Cited by 34
Kubisch, R., Meissner, L., Krebs, S., Blum, H., Günther, M., Roidl, A., & Wagner, E. (2013) · Translational Oncology · doi:10.1593/tlo.12295 · Cited by 33
Faivre, C., Barbolosi, D., Pasquier, E., & André, N. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2095-z · Cited by 32
Self-citationWalter, B., Schrettenbrunner, I., Vogelhuber, M., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-9982-0 · Cited by 31
Salmaggi, A., Milanesi, I. M., Silvani, A., Gaviani, P., Marchetti, M., Fariselli, L., Solero, C. L., Maccagnano, C., Casali, C., Guzzetti, S., et al. (2013) · Journal of neurosurgery · doi:10.3171/2012.12.jns111893 · Cited by 31
Singh, V., Erb, U., & Zöller, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301543 · Cited by 31
The person in personalised medicine
Doz, F., Marvanne, P., & Fagot-Largeault, A. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.029 · Cited by 29
Dellapasqua, S., Bagnardi, V., Bertolini, F., Sandri, M. T., Pastrello, D., Cancello, G., Montagna, E., Balduzzi, A., Mancuso, P., Luini, A., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.01.015 · Cited by 28
Malvicini, M., Alaniz, L. D., Bayo, J., García, M. G., Piccioni, F., Fiore, E. J., Atorrasagasti, C., Aquino, J. B., Matar, P., & Mazzolini, G. D. (2012) · OncoImmunology · doi:10.4161/onci.20684 · Cited by 28
Chen, Y.-M., Fan, W.-C., Tsai, C., Liu, S.-H., Shih, J.-F., Chou, T., Wu, C.-H., Chou, K., Lee, Y.-C., Perng, R.-P., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182121c09 · Cited by 28
Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study.
Zustovich, F., Landi, L. M., Lombardi, G., Galli, L., Porta, C., AMOROSO, D., Fontana, A., Andreuccetti, M., Galli, C., Falcone, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2080 · Cited by 26
Foy, K. C., Miller, M. J., Moldovan, N. I., Božanović, T., Carson, W. E., & Kaumaya, P. T. P. (2012) · OncoImmunology · doi:10.4161/onci.21057 · Cited by 22
Lasalvia-Prisco, E., Goldschmidt, P., Galmarini, F. C., Cucchi, S., Vázquez, J., Aghazarian, M., Lasalvia-Galante, E., Golomar, W., & Gordon, W. (2012) · Medical Oncology · doi:10.1007/s12032-012-0301-1 · Cited by 22
A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
Pallis, A. G., Chandrinos, V., Pavlakou, G., Xenidis, N., Varthalitis, I. I., Vardakis, N., Vamvakas, L. N., Kontopodis, E., Rovithi, M. N., & Georgoulias, V. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1415-9 · Cited by 22
Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow
McGuire, M. F., Enderling, H., Wallace, D. I., Batra, J. S., Jordan, M., Kumar, S., Panetta, J. C., & Pasquier, E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0310 · Cited by 22
Self-citationDoloff, J. C., Khan, N. I., Ma, J., Demidenko, E., Swartz, H. M., & Jounaïdi, Y. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789271503 · Cited by 22
Papanikolaou, X. D., Szymonifka, J. D., Rosenthal, A., Heuck, C. J., Mitchell, A., Johann, D. J., Keller, J., Waheed, S., Usmani, S. Z., van Rhee, F., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.085183 · Cited by 18
Pectasides, D. G., Papaxoinis, G., Kotoula, V., Fountzilas, H., Korantzis, I., Κούτρας, Ά., Dimopoulos, A. M., Papakostas, P., Aravantinos, G., Varthalitis, I., et al. (2011) · Oncology Reports · doi:10.3892/or.2011.1504 · Cited by 18
Fine-tuning anti-tumor immunotherapies via stochastic simulations
Caravagna, G., Barbuti, R., & d’Onofrio, A. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s4-s8 · Cited by 18
Woo, H. Y., Youn, J.-M., Bae, S. H., Jang, J. W., Hoon, J., Kim, H. L., Chun, H. J., Choi, B. G., Choi, J. Y., & Yoon, S. K. (2012) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2012.18.1.32 · Cited by 16
Hahnfeldt, P., Hlatky, L., & Klement, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3807 · Cited by 16
Generalized principles of stochasticity can be used to control dynamic heterogeneity
Liao, D., Estévez-Salmerón, L., & Tlsty, T. D. (2012) · Physical Biology · doi:10.1088/1478-3975/9/6/065006 · Cited by 12
Khan, N. (2011) · Oncology Reports · doi:10.3892/or.2011.1268 · Cited by 11
Ogata, Y., Tanaka, T., Akagi, Y., Ishibashi, N., Tsuji, Y., Matono, K., ISOBE, M., Sueyoshi, S., Kaibara, A., & Shirouzu, K. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10769 · Cited by 5
Cited by
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
Role of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Metadata
- Authors
- André, N., Carré, M., & Pasquier, E.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-06-10
- Volume
- 11
- Issue
- 7
- Pages
- 413-431
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1972146805
- Cited by
- 320
- References
- 165
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.